Patients with low-risk meningioma had a 3-year progression-free survival that modestly exceeded expectations after gross total resection followed by observation.
Pembrolizumab (Keytruda) was well tolerated and demonstrated promising antitumor activity in patients with PD-L1–positive advanced cervical squamous cell cancer.
Patrick Conway, MD, says that the demonstration drug pricing plan, which would raise payment for low-cost drugs and lower payment for high-priced drugs, is chiefly about improving outcomes.
Two headgear items, a system of applying electromagnetic currents to patients with glioblastoma and a cooling cap for individuals undergoing chemotherapy for breast cancer, are early entries in the field.
The SPINET trial is an international, phase III, randomized, double-blind study evaluating the efficacy and safety of lanreotide (Somatuline Depot) plus best supportive care compared with placebo plus best supportive care in patients with well-differentiated, metastatic and/or unresectable, typical or atypical lung neuroendocrine tumors.
Joshua Bauml, MD, discusses the evolution of EGFR-targeted therapies, resistance mutations in patients with non–small cell lung cancer, the evolution of next-generation sequencing, and ongoing trials that could have an impact in this space.
Katherine Thornton, MD, discusses the potential that immunotherapy agents could have in the field of sarcoma, as well as the role of genomic profiling in understanding the patients who may benefit from select treatments.
Regular screening for cervical cancer was found to be associated with an overall mortality prevention rate of 83%.
Patients with endometrial and cervical cancer reported significantly less acute gastrointestinal toxicity when treated with pelvic intensity-modulated radiation therapy as opposed to standard pelvic radiation therapy.
When it comes to health coverage, most Americans face an unnerving reality—they have no idea what is covered under their health insurance policy until they are affected by illness or disease.